Total Payments
$142,430
2021 Payments
$940.00
Companies
11
Transactions
154
Medicare Patients
237
Medicare Billing
$25,815
Payment Breakdown by Category
Consulting$113,100 (79.4%)
Other$14,437 (10.1%)
Travel$8,416 (5.9%)
Research$4,117 (2.9%)
Food & Beverage$2,317 (1.6%)
Education$43.36 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $113,100 | 28 | 79.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,437 | 19 | 10.1% |
| Travel and Lodging | $8,416 | 36 | 5.9% |
| Unspecified | $4,117 | 9 | 2.9% |
| Food and Beverage | $2,317 | 59 | 1.6% |
| Education | $43.36 | 3 | 0.0% |
Payments by Type
General
$138,313
145 transactions
Research
$4,117
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $39,406 | 35 | $0 (2018) |
| AbbVie Inc. | $25,936 | 33 | $0 (2020) |
| Janssen Biotech, Inc. | $24,637 | 36 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $21,175 | 19 | $0 (2020) |
| PFIZER INC. | $11,249 | 14 | $0 (2021) |
| Takeda Development Center Americas, Inc. | $6,281 | 4 | $0 (2017) |
| Janssen Global Services, LLC | $6,273 | 8 | $0 (2017) |
| F. Hoffmann-La Roche AG | $4,050 | 1 | $0 (2019) |
| Celgene Corporation | $3,375 | 1 | $0 (2020) |
| Synergy Pharmaceuticals Inc | $33.36 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $940.00 | 1 | PFIZER INC. ($940.00) |
| 2020 | $13,646 | 10 | Janssen Biotech, Inc. ($3,750) |
| 2019 | $28,481 | 24 | Takeda Pharmaceuticals U.S.A., Inc. ($11,307) |
| 2018 | $31,185 | 38 | Merck Sharp & Dohme Corporation ($16,198) |
| 2017 | $68,178 | 81 | AbbVie, Inc. ($25,232) |
All Payment Transactions
154 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/23/2021 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/16/2020 | Celgene Corporation | ZEPOSIA (Drug) | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| Category: Neuroscience | ||||||
| 12/03/2020 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/13/2020 | AbbVie Inc. | HUMIRA (Biological) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: IMMUNOLOGY | ||||||
| 09/30/2020 | Janssen Biotech, Inc. | STELARA (Biological) | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: Immunology | ||||||
| 08/13/2020 | Janssen Biotech, Inc. | STELARA (Biological) | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: Immunology | ||||||
| 07/03/2020 | Janssen Biotech, Inc. | STELARA (Biological) | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: Immunology | ||||||
| 07/02/2020 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 04/21/2020 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $1,400.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 02/15/2020 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 01/23/2020 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $51.28 | General |
| Category: IMMUNOLOGY | ||||||
| 12/20/2019 | Takeda Pharmaceuticals U.S.A., Inc. | Entyvio (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $321.43 | General |
| Category: Lower GI | ||||||
| 12/02/2019 | Takeda Pharmaceuticals U.S.A., Inc. | Entyvio (Biological) | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| Category: Lower GI | ||||||
| 11/21/2019 | PFIZER INC. | XELJANZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $330.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/20/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 08/19/2019 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $4,050.00 | General |
| 07/10/2019 | PFIZER INC. | XELJANZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $3,200.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/12/2019 | Shire North American Group Inc | GATTEX (Drug) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: INTERNAL MEDICINE | ||||||
| 06/11/2019 | Takeda Pharmaceuticals U.S.A., Inc. | Entyvio (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $124.94 | General |
| Category: Lower GI | ||||||
| 06/07/2019 | PFIZER INC. | XELJANZ (Drug) | Education | In-kind items and services | $10.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/19/2019 | Takeda Pharmaceuticals U.S.A., Inc. | Entyvio (Biological) | Food and Beverage | In-kind items and services | $61.05 | General |
| Category: Lower GI | ||||||
| 04/30/2019 | Janssen Biotech, Inc. | STELARA (Biological) | Consulting Fee | Cash or cash equivalent | $7,000.00 | General |
| Category: Immunology | ||||||
| 04/30/2019 | Janssen Biotech, Inc. | STELARA (Biological) | Travel and Lodging | In-kind items and services | $1,240.29 | General |
| Category: Immunology | ||||||
| 04/30/2019 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $101.06 | General |
| Category: Immunology | ||||||
| 04/30/2019 | Janssen Biotech, Inc. | STELARA (Biological) | Travel and Lodging | Cash or cash equivalent | $71.54 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,610 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 2 | 30 | 30 | $5,560 | $1,333 |
| 2020 | 8 | 207 | 271 | $143,867 | $24,482 |
Total Patients
237
Total Services
301
Medicare Billing
$25,815
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 17 | 17 | $3,740 | $962.41 | 25.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 13 | 13 | $1,820 | $370.90 | 20.4% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 37 | 37 | $55,204 | $4,406 | 8.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 26 | 45 | $9,900 | $3,426 | 34.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Facility | 2020 | 14 | 14 | $29,568 | $3,171 | 10.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 18 | 30 | $8,895 | $2,937 | 33.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 22 | 36 | $7,465 | $2,615 | 35.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 32 | 41 | $5,985 | $2,542 | 42.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 11 | $3,560 | $1,759 | 49.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 11 | 21 | $2,831 | $1,308 | 46.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 22 | 22 | $5,241 | $1,228 | 23.4% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 14 | 14 | $15,218 | $1,090 | 7.2% |
About Dr. Mark Osterman, MD
Dr. Mark Osterman, MD is a Gastroenterology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/23/2007. The National Provider Identifier (NPI) number assigned to this provider is 1669526851.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Osterman, MD has received a total of $142,430 in payments from pharmaceutical and medical device companies, with $940.00 received in 2021. These payments were reported across 154 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($113,100).
As a Medicare-enrolled provider, Osterman has provided services to 237 Medicare beneficiaries, totaling 301 services with total Medicare billing of $25,815. Data is available for 2 years (2020–2021), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Philadelphia, PA
- Active Since 01/23/2007
- Last Updated 03/14/2016
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1669526851
Products in Payments
- STELARA (Biological) $18,652
- Entyvio (Biological) $17,683
- Humira (Biological) $14,204
- XELJANZ (Drug) $11,249
- SIMPONI (Biological) $7,029
- REMICADE (Biological) $5,229
- ZEPOSIA (Drug) $3,375
- ENTYVIO (Biological) $3,200
- HUMIRA (Biological) $651.28
- Trulance (Drug) $33.36
- GATTEX (Drug) $15.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Philadelphia
Xiaoli Ma, Md, MD
Gastroenterology — Payments: $717,441
Gastroenterology $717,441
Gary Lichtenstein, Md, MD
Gastroenterology — Payments: $416,696
Gastroenterology $416,696
Dr. Neilanjan Nandi, Md, MD
Gastroenterology — Payments: $334,815
Gastroenterology $334,815
Dr. David Lichtenstein, M.d, M.D
Gastroenterology — Payments: $263,694
Gastroenterology $263,694
James Lewis, Md, MD
Gastroenterology — Payments: $229,188
Gastroenterology $229,188
Dr. Oleg Volchonok, M.d, M.D
Gastroenterology — Payments: $116,291
Gastroenterology $116,291